Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families

European Journal of Human Genetics

Volumn 21, Issue 8, 2013, Pages 883-886

  De Garibay, Gorka Ruiz ^a   Díaz, Avellaneda ^a   Gaviña, Belén ^a   Romero, Atocha ^a   Garre, Pilar ^a   Vega, Ana ^a   Blanco, Ana ^b   Tosar, Alicia ^a   Díez, Orland ^c   Pérez Segura, Pedro ^a   Díaz Rubio, Eduardo ^a   Caldés, Trinidad ^a   De La Hoya, Miguel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

FA; FANCP; Genetic testing; Hereditary breast cancer; SLX4

Indexed keywords

FANCONI ANEMIA PROTEIN; SLX4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; COMPUTER MODEL; CONTROLLED STUDY; FEMALE; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HUMAN; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FANCONI ANEMIA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; OVARIAN NEOPLASMS; PEDIGREE; RECOMBINASES;

EID: 84880916888     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.268     Document Type: Article

References (18)

1. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P: Genetic susceptibility for breast cancer: How many more genes to be found? Crit Rev Oncol Hematol 2007; 63: 125-149
2. Moldovan GL, D'Andrea AD: How the fanconi anemia pathway guards the genome. Annu Rev Genet 2009; 43: 223-249
3. Howlett NG, Taniguchi T, Olson S et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609
4. Seal S, Thompson D, Renwick A et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38: 1239-1241
5. Rahman N, Seal S, Thompson D et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167
6. Meindl A, Hellebrand H, Wiek C et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-414
7. Park DJ, Lesueur F, Nguyen-Dumont T et al: Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012; 90: 734-739
8. Stoepker C, Hain K, Schuster B et al: SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011; 43: 138-141
9. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A: Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011; 43: 142-146
10. Landwehr R, Bogdanova NV, Antonenkova N et al: Mutation analysis of the SLX4/FANCP gene in hereditary breast cancer. Breast Cancer Res Treat 2011; 130: 1021-1028
11. Fernández-Rodri'guez J, Quiles F, Blanco I et al: Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families. BMC Cancer 2012; 12: 84
12. Catucci I, Colombo M, Verderio P et al: Sequencing analysis of SLX4/FANCP gene in Italian familial breast cancer cases. PLoS One 2012; 7: E31038
13. Meijers-Heijboer H, van den Ouweland A, Klijn J et al: CHEK2-Breast Cancer Consortium, low-penetrance susceptibility to breast cancer due to CHEK2(.*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59
14. Svendsen JM, Smogorzewska A, Sowa ME et al: Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009; 138: 63-77
15. Osorio A, Endt D, Fernández F et al: Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mol Genet 2012; 21: 2889-2898
16. Yamamoto KN, Kobayashi S, Tsuda M et al: Involvement of SLX4 in interstrand crosslink repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci USA 2011; 108: 6492-6496
17. Oldenburg RA, Kroeze-Jansema K, Kraan J et al: The CHEK2. *1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003; 63: 8153-8157
18. Walsh T, Lee MK, Casadei S et al: Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107: 12629-12633